Canada’s Drug Review Process Needs Enhancements to Meet the Needs of Canadians
Canadian Diabetes Association’s report provides a vision to enhance the
nation’s drug review process
TORONTO, April 23, 2012 /PRNewswire/ – According to a new report by the
Canadian Diabetes Association, despite improvements to Canada’s drug
review process since the introduction of the Common Drug Review,
significant challenges remain with the overall drug review process,
making it particularly difficult for those living with chronic
conditions such as diabetes to get equal and timely access to
medications they need to protect their health.
“This year marks the ten-year anniversary of the inception of the Common
Drug Review (CDR) and while it has resulted in improvements within drug
reviews, challenges still remain affecting the overall process,” says
Michael Cloutier, President and CEO, Canadian Diabetes Association.
“The Association is advocating for further enhancements to the CDR
within the overall drug review process based on examples of best
practices in drug review processes internationally.”
Based on the Association’s report, In the Balance: A Renewed Vision for the Common Drug Review, the patchwork of public and private drug plans across Canada is
failing to meeting the needs of Canadians, especially those with
chronic disease who do not fall under specific public coverage or
private insurance through employers or other sources.
Although a primary motivation for establishing the CDR was to provide
more timely and improved access to newer and more efficient drugs as
clinically appropriate, location continues to influence access to
prescription medication covered under participating drug plans.
British Columbia and Prince Edward Island had among the lowest
percentages of drugs approved, and this has continued to be the case
since the introduction of the CDR. Conversely, Saskatchewan and New
Brunswick had among the highest percentages of drugs approved, and this
has continued to be the case since the introduction of the CDR. (See
Significant variations in the length of time also exist for drug funding
decisions across participating drug plans. For provinces west of
Quebec, the medium average review time has increased, while for those
located east of Quebec, it has decreased. While certain jurisdictions
have seen some improvements, the shortest review times in Canada are
still far longer than those in peer countries.
In contrast, examples of drug review processes internationally have
potential to improve access to medications across Canada through
reducing timelines for approvals and optimizing patient engagement.
“We encourage CADTH to work closely with jurisdictional authorities,
patient group representatives and industry towards further improvements
and continuous change of the CDR process to meet the needs of all
Canadians and our public healthcare system,” adds Cloutier.
Visit diabetes.ca/inthebalance to review the full report In the Balance: A Renewed Vision for the Common Drug Review.
About the Canadian Diabetes Association
The Canadian Diabetes Association is a registered charitable
organization, leading the fight against diabetes by helping people with
diabetes live healthy lives while we work to find a cure. Our
professional staff and more than 20,000 volunteers provide education
and services to help people in their daily fight against the disease,
advocate on behalf of people with diabetes for the opportunity to
achieve their highest quality of life, and break ground towards a cure.
Please visit diabetes.ca, join us on
facebook.com/CanadianDiabetesAssociation, follow us on Twitter
@DiabetesAssoc, or call 1-800-BANTING (226-8464).
SOURCE Canadian Diabetes Association